資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31038
|
| 標題: | Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis |
| 作者: | Liao, Kuang-Ming
Chao, Tung-Bo
Tian, Yu-Feng
Lin, Ching-Yih
Lee, Sung-Wei
Chuang, Hua-Ying
Chan, Ti-Chun
Chen, Tzu-Ju
Hsing, Chung-Hsi
Sheu, Ming-Jen
Li, Chien-Feng |
| 貢獻者: | Chi Mei Med Ctr, Dept Internal Med
Yuans Gen Hosp, Dept Colorectal Surg
Meiho Univ, Dept Hlth Business Adm
Chi Mei Med Ctr, Div Gen Surg
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Chi Mei Med Ctr, Dept Internal Med
Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management
Chi Mei Med Ctr, Dept Radiat Oncol
Chi Mei Med Ctr, Dept Pathol
Chi Mei Med Ctr, Dept Anesthesiol
Natl Hlth Res Inst, Natl Inst Canc Res
Southern Taiwan Univ Sci & Technol, Dept Biotechnol |
| 關鍵字: | PSAT1
Nasopharyngeal carcinoma
prognosis
trials |
| 日期: | 2016 |
| 上傳時間: | 2018-01-18 11:40:22 (UTC+8) |
| 出版者: | Ivyspring Int Publ |
| 摘要: | Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR=2.856, 95% CI 1.599 to 5.101), DMFS (HR=3.305, 95% CI 1.720 to 6.347), LRFS (HR=2.834, 95% CI 1.376 to 5.835), and OS HR=2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC. |
| 關聯: | Journal of Cancer, v.7 n.9, pp.1088-1094 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 31038.pdf | | 742Kb | Adobe PDF | 212 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1163 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
